Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374873 | 0.90 | FOLH1 (0.46) | FOLH1GRM3NAALAD2 | |
| SCHEMBL7781132 | 0.87 | FOLH1 (0.46) | FOLH1CA2MAPK1GRM3 | |
| SCHEMBL1373605 | 0.83 | FOLH1 (0.48) | FOLH1GRM3NAALAD2 | |
| SCHEMBL1374881 | 0.77 | CPA3 (0.54) | FOLH1MAPK1 | |
| SCHEMBL7605857 | 0.77 | FOLH1 (0.47) | FOLH1GRM3NAALAD2 | |
| SCHEMBL1377510 | 0.75 | FOLH1 (0.52) | FOLH1GRM3NAALAD2 | |
| SCHEMBL3446776 | 0.75 | CA2 (0.65) | FOLH1CA2MAPK1GRM3 | |
| SCHEMBL4401256 | 0.75 | AKR1B1 (0.56) | — | |
| SCHEMBL9323099 | 0.75 | AKR1B1 (0.50) | — | |
| SCHEMBL27656177 | 0.73 | CA2 (0.63) | FOLH1CA2MAPK1GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| US-5902817-A | 2-SULFINYL OR SULFONYLPENTANDIOIC ACIDS; INHIBITORS OF N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE; GLUTAMATE ABNORMALITIES; PROSTATES; ANTIEPILEPTIC AND -ISCHEMIC AGENTS; STROKES; ANALGESICS; NERVOUS SYTEM INJURIES; | GUILFORD PHARMACEUTICALS INC. (US) | 1999-05-11 | — | — | US | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-3777898-B1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE INC (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5902817-A | 2-SULFINYL OR SULFONYLPENTANDIOIC ACIDS; INHIBITORS OF N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE; GLUTAMATE ABNORMALITIES; PROSTATES; ANTIEPILEPTIC AND -ISCHEMIC AGENTS; STROKES; ANALGESICS; NERVOUS SYTEM INJURIES; | GUILFORD PHARMACEUTICALS INC. (US) | 1999-05-11 | — | — | US | disclosed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CA2 1961/4885MAPK1 4290/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | FOLH1 1/4885CA2 1961/4885MAPK1 4290/4885 |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | FOLH1 56/4885CA2 382/4885MAPK1 4166/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | FOLH1 157/4885CA2 3181/4885MAPK1 4113/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | FOLH1 1/4885CA2 18/4885MAPK1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.